Related references
Note: Only part of the references are listed.Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma
Carlos H. Barrios et al.
CANCER (2012)
Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
Bernard Escudier et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period
Carolyn D. Britten et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Sunitinib in patients with metastatic renal cell carcinoma
Robert J. Motzer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
AM O'Farrell et al.
BLOOD (2003)
The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer
W Kim et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2003)
Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma:: Relationship to clinicopathological parameters
K Kondo et al.
GENES CHROMOSOMES & CANCER (2002)
The von Hippel-Lindau tumor suppressor gene
K Kondo et al.
EXPERIMENTAL CELL RESEARCH (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Systemic therapy for renal cell carcinoma
RJ Motzer et al.
JOURNAL OF UROLOGY (2000)